Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors

The American Journal of Cardiology

Volumn 72, Issue 14, 1993, Pages 1031-1037

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MUSCLE ENZYME; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HEART DEATH; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFE TABLES; MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; PRAVASTATIN; RISK FACTORS; SMOKING; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME;

EID: 0027507820     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9149(93)90858-A     Document Type: Article

References (25)

1. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
2. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
3. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham Study
4. The Lipid Research Clinics Coronary Primary Prevention Trial results I reduction in incidence of coronary heart disease
5. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men
6. Report of the National Cholesterol Education Program Expert Panel on detection evaluation and treatment of high blood cholesterol in adults
7. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia, I: a dose-response study
8. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia, II: once-daily versus twice-daily dosing
9. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study
10. The clinical pharmacology of SQ 31,000 (CS 514) in healthy subjects
11. Pharmacokinetics, pharmacodynamics and safety of pravastatin sodium, a potent inhibitor of HMG-CoA reductase, in healthy volunteers
12. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
13. Report of the Conference on Low Blood Cholesterol: mortality associations
14. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials
15. Might treatment of hypercholesterolemia increase non-cardiac mortality
16. Health policy on blood cholesterol: time to change directions
17. Should there be a moratorium on the use of cholesterol lowering drugs?
18. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence
19. Platelet activation by plasma lipoproteins
20. Increased blood viscosity and fibrinolytic inhibitor in type II hyperlipoproteinaemia
21. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans
22. Abnormalities of blood rheology in familial hypercholesterolemia: effects of treatment
23. 2 synthesis in type IIa hypercholesterolemic patients
24. Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolemia at risk of coronary heart disease
25. Arteriographic view of treatment to achieve regression of coronary atherosclerosis and to prevent plaque disruption and clinical cardiovascular events